Gland Pharma Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Five-Star Business Finance Ltd, Sterlite Technologies Ltd, Can Fin Homes Ltd, KSB Ltd are among the other stocks to see a surge in volumes on NSE today, 09 April 2024.

Gland Pharma Ltd recorded volume of 136.71 lakh shares by 14:14 IST on NSE, a 68.49 times surge over two-week average daily volume of 2.00 lakh shares. The stock lost 3.13% to Rs.1,801.45. Volumes stood at 8.46 lakh shares in the last session.

Five-Star Business Finance Ltd notched up volume of 59.94 lakh shares by 14:14 IST on NSE, a 9.49 fold spurt over two-week average daily volume of 6.32 lakh shares. The stock slipped 3.21% to Rs.736.10. Volumes stood at 1.66 lakh shares in the last session.

Sterlite Technologies Ltd saw volume of 314.37 lakh shares by 14:14 IST on NSE, a 7.33 fold spurt over two-week average daily volume of 42.88 lakh shares. The stock increased 9.85% to Rs.139.90. Volumes stood at 17.71 lakh shares in the last session.

Can Fin Homes Ltd clocked volume of 26.36 lakh shares by 14:14 IST on NSE, a 7.16 times surge over two-week average daily volume of 3.68 lakh shares. The stock gained 1.03% to Rs.807.20. Volumes stood at 2.92 lakh shares in the last session.

KSB Ltd clocked volume of 1.16 lakh shares by 14:14 IST on NSE, a 5.16 times surge over two-week average daily volume of 22384 shares. The stock gained 3.60% to Rs.4,127.45. Volumes stood at 19959 shares in the last session.

Powered by Capital Market - Live News

Eribulin injection is used to treat breast cancer that has spread to other parts of the body and that has already been treated with certain other chemotherapy medications.

Eribulin Mesylate Injection is expected to be the first generic approval on the market and the drug maker expects to launch this drug in the near term through its marketing partner.

According to IQVIA, Eribulin Mesylate Injection has sales of approximately $92 million in the US for twelve months ending in February 2024.

The pharmaco is co-developing several complex injectables, including this product, with Orbicular Pharmaceutical Technologies.

Gland Pharma is one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.

The company’s consolidated net profit fell 17.28% to Rs 191.86 crore in Q3 FY24 crore despite of 64.68% jump in revenue from operations to Rs 1,545.2 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News

Gland Pharma has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).

The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner.

The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA

Powered by Capital Market - Live News

Gland Pharma has allotted 2,400 equity shares under ESOS on 25 March 2024. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs. 164,710,523 /- comprising of 164,710,523 Equity shares of face value Re.1/- each.

Powered by Capital Market - Live News